AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issuance of Letter of Confirmation under Regulation 39(3) of SEBI (LODR) Regulations, 201523-01-2023
23-01-2023
AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Considering And Taking On Record Unaudited Consolidated & Standalone Financial Results Of The Company For The Third Quarter And Nine Months Ended 31St December 2022.
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/02/2023 ,inter alia, to consider and approve unaudited consolidated & standalone financial results of the Company for the third quarter and nine months ended 31st December 2022.23-01-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 20, 2023 for Aayush Agrawal, trustee Aayush Agrawal Trust20-01-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 20, 2023 for Ravi P Agrawal, Trustee Ravi Agrawal Trust20-01-2023
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on January 17, 2023 for Aayush Agrawal, Trustee Aayush Agrawal Trust17-01-2023
AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are pleased to enclose herewith certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st December 2022 received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company.09-01-2023
AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and 'Ajanta's Code of Conduct for Insiders', the Trading Window for dealing in securities of the Company shall remain closed for Designated Persons (as defined in the Code) from close of business hours of Friday, 30th December 2022 till 48 hours after the declaration of Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December 2022.30-12-2022
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 22, 2022 for Ravi P Agrawal, Trustee Ravi Agrawal Trust23-12-2022
AJANTA PHARMA LTD. - 532331 - Sale Of Equity Shares Of Ajanta Pharma Limited By Some Of The Promoter(S)
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that following Promoter(s) of the Company have sold 4.38% shares today i.e. 22nd December 2022, as detailed below: 1) Aayush M. Agrawal, trustee Aayush Agrawal Trust has sold 38,78,975 shares (3.03%) 2) Ravi P. Agrawal, Trustee Ravi Agrawal Trust has sold 17,23,989 shares (1.35%) The above two promoters do not have any executive role in the company and propose to utilise these funds for financing their respective private businesses, including repayment of loans taken against pledge of shares of the Company. Please find attached herewith disclosures received pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, in respect of aforementioned sale transactions.22-12-2022
Promoter entities to sell 4.6% stake in Ajanta Pharma via block deal Thursday
Through the sale the entities are looking at raising close to Rs 650 crore.21-12-2022